Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 comparison of liquid and lyophilized MenC-CRM vaccines in healthy toddlers
2011-000395-34Phase 2Completed
- Sponsor
- Novartis
- Start
- Jul 2011
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of Meningococcal group C polysaccharide conjugate vaccine and meningococcal group c-crm197 conjugate vaccine in meningococcal disease (3 arms), sponsored by Novartis. Primary endpoint: hSBA GMTs against serogroup C at day 29 for MenC-CRM liquid and MenC-CRM EMV groups. Started Jul 2011; status: completed.
02
Drugs
Meningococcal group C polysaccharide conjugate vaccinemeningococcal group c-crm197 conjugate vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on 2011-000395-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000395-34.